ALGS Aligos Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ALGS matters now
Aligos Therapeutics, Inc. (ALGS) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.77 with +0.59% on the session and $41.9M in market capitalization; recent performance reads 1-month +1.93% and YTD -43.35%.
The latest financial table shown here is Q1 2026, with revenue of $2.8M, net income of $-23.0M, and EPS of $-2.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -260.7%.
The latest indexable market news headline is "Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes BLATT LAWRENCE filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.73
P/S
6.94
EV/EBITDA
-0.08
DCF Value
$0.06
FCF Yield
-260.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.0%
Operating Margin
-2033.4%
Net Margin
-1919.7%
ROE
-139.5%
ROA
-139.9%
ROIC
-212.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.8M | $-23.0M | $-2.21 |
| Q4 2025 | $169.0K | $-19.9M | $-1.91 |
| FY 2025 | $2.2M | $-24.2M | $-2.45 |
| Q3 2025 | $741.0K | $-31.5M | $-3.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$20.00
Target (Median)
$20.00
Target Range
$20.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.24
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.